The effectiveness of farmapram (alprazolam) in the treatment of panic disorder is evidenced by numerous comparative studies. A number of studies indicate that in the treatment of panic disorder, compared to other benzodiazepine tranquilizers, farmapram to a greater extent reduces the frequency of panic attacks, reduces the severity of anxiety and depressive symptoms. If partial improvement is taken into account, alprazolam is effective in 80% of cases. It is considered that in this respect the effect of alprazolam is comparable only to clonazepam. It was found that alprazolam at a mean dose of 4 to 7 mg/sug. was more effective than placebo during the 4 weeks of follow-up. At the same time, there was no direct correlation between the drug concentration in blood and the effectiveness of therapy. This means that treatment efficacy depends to a greater extent not on the drug dose, but on clinical and psychopathological factors. In addition, it is indicated that the drug acts not only on the anxiety of waiting, but also on the symptomatology of panic attacks themselves, reducing their severity and preventing the development of repeated panic attacks. The dosage range of alprazolam in the treatment of panic disorder is wider than in the treatment of other anxiety conditions and is up to 10 mg/day. (average 2-6 mg/day) divided into 3-4 doses.
Numerous studies have focused on the use of alprazolam in generalized anxiety disorder (GAD). GAD symptomatology is effectively reduced on therapy with alprazolam in an average daily dosage of 0.5-4.0 mg divided into 3-4 doses, in different age groups of patients, as confirmed by numerous placebo-controlled studies. At the same time, it is established that, in comparison with other benzodiazepine tranquilizers, the use of alprazolam is accompanied by a smaller number of side effects. It is necessary to note and rather fast onset of effect, appearing already within the first week of treatment. Despite the high efficacy of alprazolam in the treatment of GID, antidepressants are currently preferred for the treatment of this pathology. However, even in this case, the role of benzodiazepines in GST treatment cannot be underestimated. Taking into account that the effect of antidepressants becomes apparent only after several weeks of therapy, the use of benzodiazepines at the beginning of treatment for anxiety and insomnia has no alternative yet. Because of the risk of drug dependence, it is recommended that alprazolam be used for several weeks, followed by gradual withdrawal. In cases where this period is not sufficient for the development of a sustained therapeutic effect, longer use of the drug is possible with careful dynamic monitoring.
In the study of alprazolam effectiveness in patients with GERD manifested by irritable bowel syndrome, a significant reduction both in anxiety symptoms (in 98% of patients) and gastrointestinal complaints (in 89% of patients) was observed after 4 weeks of therapy. The drug has also proven itself in the treatment of anxiety in alcohol withdrawal states.